Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific...
CGTN: 99.9% handled: How CPPCC proposals work in consultative democracy
CGTN published an article showing how China's top political advisory body plays its role in the whole process of people's democracy and highlighting how it facilitates Chinese modernization. BEIJING, March 4, 2025 /PRNewswire/ -- As a political...
Ericsson Annual Report 2024 published
The Annual Report 2024 available for download and printed version available for order The Annual Report 2024 publication consists of Ericsson's Financial report 2024, the Corporate Governance report 2024, the Remuneration report 2024 and the...
MediBeacon® Transdermal GFR System receives device approval in China
Peer-reviewed articles on MediBeacon technology published Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in...
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine
HONG KONG, Jan. 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4...
Greater Insurability of Climate Risk is Key to Global Economic Resilience: Aon Catastrophe Report
Annual report reveals 60 percent of economic damage caused by catastrophes in 2024 was uninsured Insured losses reached $145 billion globally – the sixth costliest year on record DUBLIN, Jan. 22, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading...
The BioCircular Materials Alliance initiated by Spiber welcomes new partners including Stella McCartney and publishes its first Progress Report
Stella McCartney, Marzotto Wool Manufacturing Srl, Fashion for Good, and 13 new companies and organizations have joined the BioCircular Materials Alliance (the "Alliance"), led by biomaterials pioneer Spiber. The Alliance published its first...
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
Free information from the National Comprehensive Cancer Network offers information on how and why to access genetic counseling and testing for multiple hereditary cancers PLYMOUTH MEETING, Pa., Jan. 16, 2025 /PRNewswire/ -- Today, the National...
Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (developed...